01 March 2022 Lysarc
ARCs/TECs day at the SFH congress
10 February 2022 Lysarc
Launch of the VERLEN study
VERLEN est une étude qui vise à évaluer l'efficacité d'une nouvelle com...
07 February 2022 Calym
RedTalks Season2#4: Could polatuzumab dethron...
05 January 2022 Calym
RedTalks Season2#3: Circulating tumor DNA (ct...
29 December 2021 Calym
CALYM: strong dynamics engaged with FINDMED
13 December 2021 Lysarc
The 3000th patient included in REALYSA –...
10 December 2021 Lysarc
ASH 2021: LYSA and LYSARC to present their si...
08 December 2021 Calym
AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING...
01 December 2021 Calym
A STRUCTURING INTEGRATING THE ENTIRE VALUE CH...
29 November 2021 Calym
Congratulations to the 2 new winners of the C...
24 November 2021 Calym
ANTICANCER CELL THERAPY GROUP AND INSTITUT CA...
21 November 2021 Lysa
LYSARC – Review of the 2020 Assessment ...
LYSARC - 2020 Review and outlook for 2021